TY - JOUR
T1 - Biomarkers in Progressive Fibrosing Interstitial Lung Disease
T2 - Optimizing Diagnosis, Prognosis, and Treatment Response
AU - Bowman, Willis S.
AU - Echt, Gabrielle A.
AU - Oldham, Justin M.
N1 - Publisher Copyright:
© Copyright © 2021 Bowman, Echt and Oldham.
PY - 2021/5/10
Y1 - 2021/5/10
N2 - Interstitial lung disease (ILD) comprises a heterogenous group of diffuse lung disorders that commonly result in irreversible pulmonary fibrosis. While idiopathic pulmonary fibrosis (IPF) is the prototypical progressive fibrosing ILD (PF-ILD), a high proportion of patients with other ILD subtypes develop a PF-ILD phenotype. Evidence exists for shared pathobiology leading to progressive fibrosis, suggesting that biomarkers of disease activity may prove informative across the wide spectrum of ILDs. Biomarker investigation to date has identified a number of molecular markers that predict relevant ILD endpoints, including disease presence, prognosis, and/or treatment response. In this review, we provide an overview of potentially informative biomarkers in patients with ILD, including those suggestive of a PF-ILD phenotype. We highlight the recent genomic, transcriptomic, and proteomic investigations that identified these biomarkers and discuss the body compartments in which they are found, including the peripheral blood, airway, and lung parenchyma. Finally, we identify critical gaps in knowledge within the field of ILD biomarker research and propose steps to advance the field toward biomarker implementation.
AB - Interstitial lung disease (ILD) comprises a heterogenous group of diffuse lung disorders that commonly result in irreversible pulmonary fibrosis. While idiopathic pulmonary fibrosis (IPF) is the prototypical progressive fibrosing ILD (PF-ILD), a high proportion of patients with other ILD subtypes develop a PF-ILD phenotype. Evidence exists for shared pathobiology leading to progressive fibrosis, suggesting that biomarkers of disease activity may prove informative across the wide spectrum of ILDs. Biomarker investigation to date has identified a number of molecular markers that predict relevant ILD endpoints, including disease presence, prognosis, and/or treatment response. In this review, we provide an overview of potentially informative biomarkers in patients with ILD, including those suggestive of a PF-ILD phenotype. We highlight the recent genomic, transcriptomic, and proteomic investigations that identified these biomarkers and discuss the body compartments in which they are found, including the peripheral blood, airway, and lung parenchyma. Finally, we identify critical gaps in knowledge within the field of ILD biomarker research and propose steps to advance the field toward biomarker implementation.
KW - biomarker
KW - connective tissue disease-associated interstitial lung disease
KW - hypersensitivity pneumonitis
KW - idiopathic pulmonary fibrosis
KW - interstitial lung disease
KW - progressive fibrosing ILD
UR - http://www.scopus.com/inward/record.url?scp=85107175267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107175267&partnerID=8YFLogxK
U2 - 10.3389/fmed.2021.680997
DO - 10.3389/fmed.2021.680997
M3 - Review article
AN - SCOPUS:85107175267
VL - 8
JO - Frontiers in Medicine
JF - Frontiers in Medicine
SN - 2296-858X
M1 - 680997
ER -